Regulatory Risk Management in Nanotechnology: Proactive Steps to Take Now for Security in the Future
September 27, 2007
Foley is proud to introduce its Nanotechnology Web conference series, The Business of Nanotech. This series is designed to keep participants up-to-date on the latest developments in the field of nanotechnology and the impact of those developments across industries.
In this, our inaugural program, we discussed Regulatory Risk Management in Nanotechnology: Proactive Steps to Take Now for Security in the Future. Specific topics included:
- The future prospects for U.S. Environmental Protection Agency (EPA) and U.S. Food and Drug Administration (FDA) regulatory activity
- Developments in self-regulatory initiatives involving industry and consumer groups
- The effects of activist opposition on the regulatory process
- Potential paths forward for the regulatory process
- Regulatory initiatives in key international markets
Speakers
- Val Giddings, President and CEO, PrometheusAB
- Mark Mansour, Partner, Foley
- Michael R. Pontrelli, Partner, Foley
People
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.